Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00255658 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: sorafenib tosylate
DRUG: temsirolimus
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)